The European Medicines Agency is ditching its policy on the proactive publication of clinical trial data as part of its decision to temporarily suspend or scale-back non-urgent activities to cope with higher-than-expected staff losses due to Brexit. As part of its efforts to protect its core activities relating to drug evaluation and supervision, the agency is also planning to limit its involvement in areas including international collaboration, guidelines development and revision, and attendance at stakeholder meetings.
The EMA had initially estimated that it would lose up to 19% of its staff as a result of it...








